Randomized Controlled Trial
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jan 7, 2021; 27(1): 107-128
Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.107
Table 4 Lipid profile
Lipid profile
Group
Baseline period
Ingestion period
P value
Cholesterol (mg/dL)Probiotic-treated194.93 ± 37.64192.20 ± 36.550.462
Placebo193.70 ± 29.47192.37 ± 29.750.412
Triglyceride (mg/dL)Probiotic-treated151.50 ± 63.92166.83 ± 75.020.162
Placebo191.40 ± 133.60187.73 ± 111.580.542
HDL (mg/dL)Probiotic-treated40.33 ± 9.7740.00 ± 9.280.691
Placebo39.93 ± 7.2940.60 ± 8.180.391
LDL (mg/dL)Probiotic-treated141.43 ± 32.17136.97 ± 33.120.182
Placebo134.50 ± 24.84133.50 ± 27.060.711
Ratio of LDL/HDLProbiotic-treated3.63 ± 0.953.55 ± 0.870.381
Placebo3.44 ± 0.703.39 ± 0.840.611

  • Citation: Rahayu ES, Mariyatun M, Putri Manurung NE, Hasan PN, Therdtatha P, Mishima R, Komalasari H, Mahfuzah NA, Pamungkaningtyas FH, Yoga WK, Nurfiana DA, Liwan SY, Juffrie M, Nugroho AE, Utami T. Effect of probiotic Lactobacillus plantarum Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults. World J Gastroenterol 2021; 27(1): 107-128
  • URL: https://www.wjgnet.com/1007-9327/full/v27/i1/107.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v27.i1.107